---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-191512"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:24:04.102564+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Oncology enters consulting agreement with former CEO Eli Wallace; equity vesting continues for 12 months

## Summary
- Dr. Wallace provides R&D advisory services for 12 months retroactive to April 21, 2026.
- Compensation: continued vesting of outstanding equity awards subject to service through each vesting date.
- Vested stock options exercisable up to 2 years after consulting termination or original expiry, whichever earlier.
- Wallace also receives Tier 1 severance benefits under the Executive Severance Plan via Separation Agreement.

## SEC filing metadata
- accession: 0001193125-26-191512
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/d68319d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-191512
- JSON: https://secwatch.observer/filing/0001193125-26-191512.json
- Plain text: https://secwatch.observer/filing/0001193125-26-191512.txt

## Key facts
- Executive change
  Pedro J. Beltran was appointed as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..
  - Action: appointed
  - Role: Member of the Board of Directors
  source text: Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm
- Executive change
  Eli Wallace resigned as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm
- Executive change
  Pedro J. Beltran was appointed as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm
- Executive change
  Eli Wallace resigned as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors
  source text: Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.